JP2021510677A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021510677A5 JP2021510677A5 JP2020534949A JP2020534949A JP2021510677A5 JP 2021510677 A5 JP2021510677 A5 JP 2021510677A5 JP 2020534949 A JP2020534949 A JP 2020534949A JP 2020534949 A JP2020534949 A JP 2020534949A JP 2021510677 A5 JP2021510677 A5 JP 2021510677A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- inhibitor
- pharmaceutical composition
- composition according
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- 239000003112 inhibitor Substances 0.000 claims 15
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 5
- 239000012453 solvate Substances 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims 3
- 208000001132 Osteoporosis Diseases 0.000 claims 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 3
- 201000010881 cervical cancer Diseases 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 201000000736 Amenorrhea Diseases 0.000 claims 2
- 206010001928 Amenorrhoea Diseases 0.000 claims 2
- 101001113483 Homo sapiens Poly [ADP-ribose] polymerase 1 Proteins 0.000 claims 2
- 206010058359 Hypogonadism Diseases 0.000 claims 2
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 claims 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 2
- 231100000540 amenorrhea Toxicity 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 235000020805 dietary restrictions Nutrition 0.000 claims 2
- 238000009802 hysterectomy Methods 0.000 claims 2
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 2
- 238000012153 long-term therapy Methods 0.000 claims 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- BOTWFBJTUJHJAI-UHFFFAOYSA-J C(C(S)CC(=O)[O-])(=O)[O-].[K+].[Au+3].C(C(S)CC(=O)[O-])(=O)[O-] Chemical compound C(C(S)CC(=O)[O-])(=O)[O-].[K+].[Au+3].C(C(S)CC(=O)[O-])(=O)[O-] BOTWFBJTUJHJAI-UHFFFAOYSA-J 0.000 claims 1
- 230000004568 DNA-binding Effects 0.000 claims 1
- 206010052337 Diastolic dysfunction Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 claims 1
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 claims 1
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 claims 1
- 102000001253 Protein Kinase Human genes 0.000 claims 1
- 229940124639 Selective inhibitor Drugs 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 101100102932 Xenopus laevis wee2-b gene Proteins 0.000 claims 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical group [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical group [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims 1
- 239000010931 gold Substances 0.000 claims 1
- 229910052737 gold Inorganic materials 0.000 claims 1
- -1 gold thiomalate calcium Chemical compound 0.000 claims 1
- ZBKIUFWVEIBQRT-UHFFFAOYSA-N gold(1+) Chemical group [Au+] ZBKIUFWVEIBQRT-UHFFFAOYSA-N 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 201000002313 intestinal cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 238000009115 maintenance therapy Methods 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229940121656 pd-l1 inhibitor Drugs 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 108060006633 protein kinase Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- AGHLUVOCTHWMJV-UHFFFAOYSA-J sodium;gold(3+);2-sulfanylbutanedioate Chemical compound [Na+].[Au+3].[O-]C(=O)CC(S)C([O-])=O.[O-]C(=O)CC(S)C([O-])=O AGHLUVOCTHWMJV-UHFFFAOYSA-J 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 229920003169 water-soluble polymer Polymers 0.000 claims 1
- 239000011701 zinc Substances 0.000 claims 1
- 229910052725 zinc Inorganic materials 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1800733.6 | 2018-01-17 | ||
| GBGB1800733.6A GB201800733D0 (en) | 2018-01-17 | 2018-01-17 | Cancer |
| PCT/GB2019/050110 WO2019141979A1 (en) | 2018-01-17 | 2019-01-16 | Selective parp1 inhibitors to treat cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021510677A JP2021510677A (ja) | 2021-04-30 |
| JP2021510677A5 true JP2021510677A5 (https=) | 2021-07-26 |
| JP7364154B2 JP7364154B2 (ja) | 2023-10-18 |
Family
ID=61256175
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020534949A Active JP7364154B2 (ja) | 2018-01-17 | 2019-01-16 | がんを治療するための選択的ｐａｒｐ１阻害剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20210052632A1 (https=) |
| EP (1) | EP3740238A1 (https=) |
| JP (1) | JP7364154B2 (https=) |
| CN (1) | CN111629757A (https=) |
| CA (1) | CA3087652A1 (https=) |
| GB (1) | GB201800733D0 (https=) |
| WO (1) | WO2019141979A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2592555A (en) * | 2019-09-27 | 2021-09-08 | Varsity Pharmaceuticals Ltd | Cancer |
| AU2022334408A1 (en) * | 2021-08-27 | 2024-02-15 | Impact Therapeutics (Shanghai), Inc. | Substituted tricyclic compounds as parp inhibitors and use thereof |
| IL314895A (en) * | 2022-02-16 | 2024-10-01 | Duke Street Bio Ltd | Pharmaceutical compound |
| US20250352539A1 (en) * | 2022-06-15 | 2025-11-20 | Astrazeneca Ab | Combination therapy for treating cancer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008144067A1 (en) * | 2007-05-21 | 2008-11-27 | Board Of Regents, University Of Texas System | Methods and compositions for treatment of cancer using oncolytic rsv activity |
| US20110190390A1 (en) * | 2010-01-05 | 2011-08-04 | Nicole Renee Murray | Methods and materials for treating pancreatic cancer |
| EP3052655B1 (en) * | 2013-09-30 | 2018-11-07 | Institute For Cancer Research D/b/a The Research Institute of Fox Chase Cancer Center | Closantel in combination with temozolomide for use in the treatment of a cancer in which is thymine dna glycosylase expressed |
| KR20180132939A (ko) * | 2016-05-03 | 2018-12-12 | 갈레라 랩스, 엘엘씨 | 암 치료를 위한 조합 요법 |
| GB2592555A (en) * | 2019-09-27 | 2021-09-08 | Varsity Pharmaceuticals Ltd | Cancer |
-
2018
- 2018-01-17 GB GBGB1800733.6A patent/GB201800733D0/en not_active Ceased
-
2019
- 2019-01-16 JP JP2020534949A patent/JP7364154B2/ja active Active
- 2019-01-16 EP EP19701902.9A patent/EP3740238A1/en not_active Withdrawn
- 2019-01-16 CN CN201980008960.3A patent/CN111629757A/zh active Pending
- 2019-01-16 US US16/959,519 patent/US20210052632A1/en not_active Abandoned
- 2019-01-16 CA CA3087652A patent/CA3087652A1/en active Pending
- 2019-01-16 WO PCT/GB2019/050110 patent/WO2019141979A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021510677A5 (https=) | ||
| Singh et al. | The emerging role of immune checkpoint inhibitors in the treatment of triple-negative breast cancer | |
| Liu et al. | NF-κB directly regulates Fas transcription to modulate Fas-mediated apoptosis and tumor suppression | |
| Lazăr et al. | New advances in targeted gastric cancer treatment | |
| Mahipal et al. | FGFR2 genomic aberrations: Achilles heel in the management of advanced cholangiocarcinoma | |
| Sorbye et al. | Age-dependent improvement in median and long-term survival in unselected population-based Nordic registries of patients with synchronous metastatic colorectal cancer | |
| US20220306688A1 (en) | KRAS G12V Mutant Binds to JAK1, Inhibitors, Pharmaceutical Compositions, and Methods Related Thereto | |
| Jensen et al. | Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer | |
| CN108464981B (zh) | 抑制tie2激酶的组合物在制备治疗癌症的药物中的用途 | |
| TW202034959A (zh) | 抗體-藥物結合物與parp抑制劑之組合 | |
| Voutsadakis | Immune blockade inhibition in breast cancer | |
| JP2023093603A (ja) | 癌を治療するための併用療法 | |
| JP2016514689A5 (https=) | ||
| IL255312B (en) | Therapeutic and diagnostic methods for cancer containing a pd–l1 binding antagonist | |
| JP2019515670A5 (https=) | ||
| TWI641385B (zh) | 抗腫瘤劑及抗腫瘤效果增強劑 | |
| Molina et al. | A phase II trial of the Src-kinase inhibitor saracatinib after four cycles of chemotherapy for patients with extensive stage small cell lung cancer: NCCTG trial N-0621 | |
| RU2016141385A (ru) | Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf | |
| RU2020113246A (ru) | Комбинация ингибитора parp и антагониста, связывающегося с осью pd-1 | |
| JP2019533651A5 (https=) | ||
| Jalal et al. | Paclitaxel plus bevacizumab in patients with chemosensitive relapsed small cell lung cancer: a safety, feasibility, and efficacy study from the Hoosier Oncology Group | |
| Power et al. | The cancer-immune set point in oesophageal cancer | |
| US20240299392A1 (en) | Methods and compositions comprising a krasg12c inhibitor and a vegf inhibitor for treating solid tumors | |
| JPWO2022270524A5 (https=) | ||
| CA3201519A1 (en) | Methods and compositions comprising a krasg12c inhibitor and a pd-l1 binding antagonist for treating lung cancer |